Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xoma
Fierce Pharma
Ligand lays out $739M for royalty aggregator compatriot Xoma
After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is being bought out by its peer Ligand Pharmaceuticals.
Fraiser Kansteiner
Apr 27, 2026 10:19am
Xoma adds another struggling biotech to its buyout roster
Dec 16, 2025 11:00am
Repare nails down XenoTherapeutics buyout
Nov 17, 2025 12:12pm
The 2025 Biotech Graveyard
Oct 31, 2025 5:00am
Xoma and Lava buyout cools with lower offer
Oct 17, 2025 2:35pm
Painted into a corner, Mural agrees to Xoma buyout
Aug 20, 2025 10:28am